Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy (DIAMOX-TEP)

Centre Antoine Lacassagne

Status

Not yet enrolling

Conditions

Cerebrovascular Circulation

Treatments

Diagnostic Test: PET scan

Study type

Interventional

Funder types

Other

Identifiers

NCT06584747

2024/27

Details and patient eligibility

About

This study compares two methods for assessing brain blood flow. PET scan will be use with a drug called Acetazolamide and compare its effectiveness to the standard scintigraphy method. The goal is to see if the PET scan is just as good as the traditional method in measuring how well the brain's blood vessels respond to the drug.

Enrollment

22 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Chronic stenosing cerebral vascular pathology (stenosis > 70% on Doppler examination or angiography).
Patient aged over 18 years.
Patient who has voluntarily agreed to participate in the study and has signed the written informed consent.
Patient affiliated with a social security system.

Exclusion criteria

Patient with stenosis less than 70% on Doppler examination or angiography.
Patient with a contraindication to 18F-FDG PET examinations: severe claustrophobia, poorly controlled diabetes during 18F-FDG PET examinations (fasting capillary blood glucose ≥ 11 mmol/L).
Patient with a contraindication to scintigraphy.
Patient with an allergy to sulfonamides (Acetazolamide DIAMOX®).
Patient enrolled in another clinical study with a specified exclusion period.
Minor patient.
Patient unable to give informed consent.
Vulnerable individuals